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Background: Exercise oscillatory ventilation (EOV) predicts poor prognosis in systolic heart failure (SHF). Mechanisms of EOV remain poorly 
understood. We investigated relationships between hemodynamics, blood gases and EOV during cardiopulmonary exercise tests (CPET).
Methods: 25 patients with SHF (age 57 ± 3 years, LV ejection fraction (EF) 0.27 ± 0.05, peak oxygen uptake 11.5 ± 3.3 ml/kg/min) underwent 
CPETs before and after 12 weeks of treatment with sildenafil or placebo.
Results: Using standard criteria to define EOV ( ≥3 cyclical oscillations of >15% baseline amplitude) we detected EOV in 68% of patients. In the 
placebo group EOV cycle length (CL) and amplitude (Amp) were highly reproducible on repeat testing (CL 62±6 sec vs. 60±6 sec, Amp 5±1L and 
6±1L, intraclass r=0.96 and r=0.9, respectively, both P<0.05). Amp was related to resting cardiac index (CI, r=-0.68), PCWP (r=0.5), PVR (r=0.55) 
and RVEF (0.67), all p<0.05. Rest and exercise PaO2 (94±13 and 96±21mmHg) and PaCO2 (37±5 and 35±5) were relatively normal and not 
significantly related to CL or Amp. Sildenafil reduced CL and Amp compared to placebo (p<0.05 for both by ANOVA). Changes in CL and Amp from 
baseline to week 12 were strongly correlated with changes in exercise CI (r=0.72 and r=0.64, both p<0.01).
Conclusion: EOV is highly reproducible and more related to hemodynamic parameters than to abnormal ventilatory drive. Attenuation of EOV by 
sildenafil merits further investigation of pharmacologic agents that may modulate EOV.
